Prestige Consumer Healthcare (PBH) vs Vera Therapeutics (VERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vera Therapeutics (VERA) has outperformed Prestige Consumer Healthcare (PBH) over the past year, losing 2.5% versus a loss of 24.4%. Over five years, VERA leads with a +98.1% price change compared with -18.1% for PBH. Prestige Consumer Healthcare is the larger company by market cap ($2.28 billion vs $2.15 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PBH | VERA |
|---|---|---|
| Share price | $48.23 | $29.88 |
| Market cap | $2.28B | $2.15B |
| 1-day change | +0.75% | +0.50% |
| YTD return | -22.40% | -41.29% |
| 1-year return | -24.36% | -2.52% |
| 5-year return | -18.06% | +98.07% |
| P/E ratio (TTM) | 13.51 | — |
| Forward P/E | 9.49 | — |
| EPS (TTM) | $3.57 | $-5.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.09B | — |
| Revenue growth (YoY) | -4.31% | — |
| Net income (latest FY) | $190.30M | $-299.62M |
| Gross margin | 54.71% | — |
| Operating margin | 28.42% | — |
| Net margin | 17.48% | — |
| 52-week high | $71.07 | $56.05 |
| 52-week low | $42.62 | $23.05 |
| Distance from 52-week high | -32.14% | -46.69% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +40.58% | +159.37% |
| Average volume | 547.31K | 2.21M |
| Shares outstanding | 47.37M | 72.06M |
| Employees | 890 | 361 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VERA has outperformed PBH by 21.8 percentage points over the past year.
About Prestige Consumer Healthcare
PBH stock →Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 361 employees
PBH vs VERA FAQ
Which is bigger, Prestige Consumer Healthcare or Vera Therapeutics?
Prestige Consumer Healthcare (PBH) is larger, with a market capitalization of $2.28B compared with $2.15B for Vera Therapeutics (VERA).
Which stock has performed better over the past year, PBH or VERA?
VERA returned -2.52% over the past 12 months, compared with -24.36% for PBH (price return, excluding dividends). Past performance does not predict future results.
Are Prestige Consumer Healthcare and Vera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.